Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Cost of Revenue (2016 - 2024)

BioCorRx's Cost of Revenue history spans 15 years, with the latest figure at $1667.0 for Q1 2024.

  • For Q1 2024, Cost of Revenue fell 80.79% year-over-year to $1667.0; the TTM value through Dec 2024 reached $1667.0, down 95.37%, while the annual FY2024 figure was $1667.0, 95.37% down from the prior year.
  • Cost of Revenue for Q1 2024 was $1667.0 at BioCorRx, down from $13053.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $28954.0 in Q4 2020 and bottomed at $632.0 in Q1 2021.
  • The 5-year median for Cost of Revenue is $3881.0 (2023), against an average of $9103.6.
  • The largest annual shift saw Cost of Revenue surged 713.26% in 2020 before it crashed 97.24% in 2021.
  • A 5-year view of Cost of Revenue shows it stood at $28954.0 in 2020, then tumbled by 91.6% to $2431.0 in 2021, then surged by 256.89% to $8676.0 in 2022, then surged by 50.45% to $13053.0 in 2023, then plummeted by 87.23% to $1667.0 in 2024.
  • Per Business Quant, the three most recent readings for BICX's Cost of Revenue are $1667.0 (Q1 2024), $13053.0 (Q4 2023), and $3881.0 (Q3 2023).